MA53548A - Formulations antiparasitaires de goût agréable - Google Patents

Formulations antiparasitaires de goût agréable

Info

Publication number
MA53548A
MA53548A MA053548A MA53548A MA53548A MA 53548 A MA53548 A MA 53548A MA 053548 A MA053548 A MA 053548A MA 53548 A MA53548 A MA 53548A MA 53548 A MA53548 A MA 53548A
Authority
MA
Morocco
Prior art keywords
parasitic
formulations
great tasting
tasting anti
great
Prior art date
Application number
MA053548A
Other languages
English (en)
Other versions
MA53548B1 (fr
Inventor
Sachin Pundlik Kolhe
Supriya Gautam Thakur
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67982187&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MA53548A publication Critical patent/MA53548A/fr
Publication of MA53548B1 publication Critical patent/MA53548B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)
MA53548A 2018-09-05 2019-09-03 Formulations antiparasitaires de goût agréable MA53548B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862727018P 2018-09-05 2018-09-05
PCT/US2019/049279 WO2020051106A1 (fr) 2018-09-05 2019-09-03 Formulations antiparasitaires de goût agréable
EP19769675.0A EP3846786B1 (fr) 2018-09-05 2019-09-03 Formulations antiparasitaires de goût agréable

Publications (2)

Publication Number Publication Date
MA53548A true MA53548A (fr) 2021-07-14
MA53548B1 MA53548B1 (fr) 2024-12-31

Family

ID=67982187

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53548A MA53548B1 (fr) 2018-09-05 2019-09-03 Formulations antiparasitaires de goût agréable

Country Status (27)

Country Link
US (1) US11896594B2 (fr)
EP (2) EP3846786B1 (fr)
JP (1) JP7241170B2 (fr)
KR (1) KR102554130B1 (fr)
CN (1) CN113038937A (fr)
AU (1) AU2019336663B2 (fr)
CA (1) CA3109543C (fr)
CL (1) CL2021000474A1 (fr)
DK (1) DK3846786T3 (fr)
ES (1) ES3002764T3 (fr)
FI (1) FI3846786T3 (fr)
HR (1) HRP20241712T1 (fr)
HU (1) HUE069712T2 (fr)
IL (1) IL281206B2 (fr)
LT (1) LT3846786T (fr)
MA (1) MA53548B1 (fr)
MD (1) MD3846786T2 (fr)
MX (1) MX2021002606A (fr)
NZ (1) NZ774180A (fr)
PH (1) PH12021550338A1 (fr)
PL (1) PL3846786T3 (fr)
PT (1) PT3846786T (fr)
RS (1) RS66315B1 (fr)
SI (1) SI3846786T1 (fr)
SM (1) SMT202400523T1 (fr)
WO (1) WO2020051106A1 (fr)
ZA (1) ZA202100950B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022066A1 (fr) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex
KR20250057155A (ko) 2017-12-15 2025-04-28 타르서스 파마수티칼스, 아이엔씨. 안검염을 치료하기 위한 이속사졸린 구충제 제제 및 방법
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
MX2021012188A (es) * 2019-04-04 2022-02-11 Tarsus Pharmaceuticals Inc Parasiticidas sistemicos de isoxazolina para el tratamiento o la profilaxis de enfermedades virales y transmitidas por vectores.
KR20230043904A (ko) 2020-07-24 2023-03-31 엘랑코 유에스 인코포레이티드 이속사졸린 화합물 및 이의 중간체의 제조 공정
EP4706683A2 (fr) * 2020-09-03 2026-03-11 Elanco Tiergesundheit AG Formulations à mâcher
EP4208157A1 (fr) 2020-09-04 2023-07-12 Elanco Us Inc. Formulations palatables
BR112023017675A2 (pt) * 2021-03-11 2023-11-14 In The Bowl Animal Health Inc Alimento canino oral e métodos para controlar infestações de carrapatos em um canino
MX2023015205A (es) * 2021-06-25 2024-01-18 Intervet Int Bv Composiciones veterinarias agradables.
KR20240051920A (ko) * 2021-06-25 2024-04-22 인 더 보울 애니멀 헬스, 인크. 고양잇과의 진드기 감염을 구제하기 위한 경구용 고양잇과 사료 및 방법
CN115671288B (zh) * 2021-07-21 2024-05-10 瑞普（天津）生物药业有限公司 一种抗寄生虫复方软咀嚼药物制剂及其制备方法与应用
CN115671040B (zh) * 2021-07-21 2024-02-27 瑞普（天津）生物药业有限公司 一种控制动物寄生虫感染的外用制剂
PE20231574A1 (es) 2023-02-24 2023-10-04 Agrovet Market S A Composicion farmaceutica que comprende fluralaner, moxidectina y praziquantel para el tratamiento de infestaciones parasitarias en animales menores

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1197215E (pt) * 2000-10-10 2006-07-31 Wyeth Corp Composicoes antelminticas
NZ548931A (en) * 2006-05-15 2008-03-28 Wyeth Corp Stabilised formulation of moxidectin
UA108641C2 (uk) * 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
HUE043949T2 (hu) * 2012-02-06 2019-09-30 Boehringer Ingelheim Animal Health Usa Inc Szisztémásan ható hatóanyagokat tartalmazó, parazitaellenes, szájon át adagolt állatgyógyászati készítmények, eljárások és alkalmazásuk
US9770440B2 (en) * 2012-04-04 2017-09-26 Intervet Inc. Solid oral pharmaceutical compositions for isoxazoline compounds
MX355843B (es) * 2012-09-07 2018-05-02 Zoetis Services Llc Combinaciones parasiticidas de isoxazolina espirociclica.
MY175703A (en) * 2012-12-19 2020-07-06 Bayer Animal Health Gmbh Tablets with improved acceptance and good storage stability
EP2983712B1 (fr) * 2013-04-12 2020-11-25 Zoetis Services LLC Composition de lactones macrocycliques, de lévamisole, d'un sucre aminé et d'un agent antiparasitaire additionnel
CA2965524C (fr) * 2014-11-03 2020-04-14 Zoetis Services Llc Composition veterinaire a macher appetissante
WO2017106812A1 (fr) 2015-12-19 2017-06-22 First Time Us Generics Llc Formulations pharmaceutiques de comprimés mous à mâcher
RU2657508C1 (ru) 2017-07-04 2018-06-14 Александр Анатольевич Хахалин Комбинированное противопаразитарное средство для лечения и профилактики гельминтозов и арахноэнтомозов плотоядных животных

Also Published As

Publication number Publication date
EP3846786B1 (fr) 2024-11-13
IL281206B1 (en) 2025-04-01
CA3109543A1 (fr) 2020-03-12
HRP20241712T1 (hr) 2025-02-14
JP2022501329A (ja) 2022-01-06
EP3846786A1 (fr) 2021-07-14
DK3846786T3 (da) 2024-12-02
BR112021004218A2 (pt) 2021-05-18
FI3846786T3 (fi) 2025-01-14
AU2019336663A1 (en) 2021-03-11
IL281206B2 (en) 2025-08-01
CA3109543C (fr) 2023-05-23
WO2020051106A1 (fr) 2020-03-12
MX2021002606A (es) 2021-05-12
SMT202400523T1 (it) 2025-01-14
US20210220360A1 (en) 2021-07-22
KR102554130B1 (ko) 2023-07-12
PH12021550338A1 (en) 2021-10-04
EP4487846A2 (fr) 2025-01-08
ZA202100950B (en) 2024-09-25
ES3002764T3 (en) 2025-03-07
CN113038937A (zh) 2021-06-25
JP7241170B2 (ja) 2023-03-16
CL2021000474A1 (es) 2021-07-19
IL281206A (en) 2021-04-29
EP4487846A3 (fr) 2025-03-19
NZ774180A (en) 2023-04-28
PT3846786T (pt) 2025-01-08
LT3846786T (lt) 2025-01-10
HUE069712T2 (hu) 2025-04-28
US11896594B2 (en) 2024-02-13
PL3846786T3 (pl) 2025-03-03
KR20210039427A (ko) 2021-04-09
RS66315B1 (sr) 2025-01-31
MD3846786T2 (ro) 2025-04-30
MA53548B1 (fr) 2024-12-31
SI3846786T1 (sl) 2025-04-30
AU2019336663B2 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
MA53548A (fr) Formulations antiparasitaires de goût agréable
EP3877521A4 (fr) Formulations de nanoparticules lipidiques
IL268697A (en) Formulations
EP3793613C0 (fr) Immunoconjugués
MA50657A (fr) Formulations de niraparib
DK3658184T3 (da) Højkoncentrerede anti-c5-antistofformuleringer
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
IL292716A (en) Pro-perfume compositions
IL288153A (en) Stabilized formulations containing anti-angptl3 antibodies
EP3746081A4 (fr) Nouvelles utilisations
IL285674A (en) Pharmaceutical formulations
IL277171A (en) Herbicidal compounds
DK3886820T3 (da) Kapselformuleringer
HUE055762T2 (hu) Nyújtott hatású készítmények
EP3831851A4 (fr) Anticorps anti-btla
IL283900A (en) Pharmaceutical combinations
IL283886A (en) Antibody formulations
DK3481420T3 (da) Antistofformuleringer
EP3782874A4 (fr) Poussette
IL280906A (en) Formulations of ag10
IL286024A (en) Stabilized formulations containing anti-il-33 antibodies
EP3454847A4 (fr) Formulations de médicaments améliorées
EP4013441A4 (fr) Formulations de larazotide
MA50068A (fr) Formulations de copanlisib
IL272167A (en) Hemopexin formulations